Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00421213
Status:
COMPLETED
Last Update Posted:
2012-07-19
First Post:
2007-01-10
Brief Title:
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
Sponsor:
Alaunos Therapeutics
Organization:
Alaunos Therapeutics
Study Overview
Official Title:
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study of safety of a new organic arsenic compound in the treatment of hematological malignancies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None